Answers are grounded in this paper and cite their sources.
Randomized trial shows improved fatigue and quality of life in patients with acute myeloid leukemia remission, indicating treatment benefits.
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial
No takes yet. Share an insight, caveat, or question.
Roboz et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: